Is the price fair?
What NRIX's price assumes
Nurix Therapeutics, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is read against sales instead: 53.7× revenue.
53.7
Price / sales · no P/E: the last twelve months did not end in a profit
- Price / book
- 4.90
Price / book · as of 2026-Q2
Details›
- Price / book2026-Q2
- 4.90
- EV / EBIToperating margin −982%: the multiple describes the denominator
- not meaningful
- Market capitalisation
- $1.81B
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.